Abstract |
Ergotamine has been used for many years in the treatment of migraine, although there is little formal clinical evidence that it is significantly more efficacious than placebo. A number of side effects associated with ergotamine have been reported in the literature, including myocardial infarction, ischaemia of limb extremities, and fibrotic changes. Long-term use has led to reported cases of ergotamine-induced headache, vascular reactivity, and subclinical ergotism. When the safety profile of this drug is considered, coupled with its debatable efficacy from a clinical review previously published, the resulting poor risk:benefit ratio brings into question the continued use of ergotamine as a migraine treatment and calls for better controlled trials of its efficacy, or lack of, in the acute treatment of migraine.
|
Authors | W J Meyler |
Journal | Cephalalgia : an international journal of headache
(Cephalalgia)
Vol. 16
Issue 1
Pg. 5-10
(Feb 1996)
ISSN: 0333-1024 [Print] England |
PMID | 8825693
(Publication Type: Journal Article, Review)
|
Chemical References |
|
Topics |
- Adverse Drug Reaction Reporting Systems
- Clinical Trials as Topic
- Dose-Response Relationship, Drug
- Ergotamine
(administration & dosage, adverse effects)
- Ergotism
(etiology)
- Extremities
(blood supply)
- Headache
(chemically induced)
- Humans
- Ischemia
(chemically induced)
- Migraine Disorders
(drug therapy)
- Myocardial Infarction
(chemically induced)
- Treatment Outcome
|